Literature DB >> 23635669

Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study.

William H Parker1, Diane Feskanich, Michael S Broder, Eunice Chang, Donna Shoupe, Cynthia M Farquhar, Jonathan S Berek, JoAnn E Manson.   

Abstract

OBJECTIVE: To report long-term mortality after oophorectomy or ovarian conservation at the time of hysterectomy in subgroups of women based on age at the time of surgery, use of estrogen therapy, presence of risk factors for coronary heart disease, and length of follow-up.
METHODS: This was a prospective cohort study of 30,117 Nurses' Health Study participants undergoing hysterectomy for benign disease. Multivariable adjusted hazard ratios for death from coronary heart disease, stroke, breast cancer, epithelial ovarian cancer, lung cancer, colorectal cancer, total cancer, and all causes were determined comparing bilateral oophorectomy (n=16,914) with ovarian conservation (n=13,203).
RESULTS: Over 28 years of follow-up, 16.8% of women with hysterectomy and bilateral oophorectomy died from all causes compared with 13.3% of women who had ovarian conservation (hazard ratio 1.13, 95% confidence interval 1.06-1.21). Oophorectomy was associated with a lower risk of death from ovarian cancer (four women with oophorectomy compared with 44 women with ovarian conservation) and, before age 47.5 years, a lower risk of death from breast cancer. However, at no age was oophorectomy associated with a lower risk of other cause-specific or all-cause mortality. For women younger than 50 years at the time of hysterectomy, bilateral oophorectomy was associated with significantly increased mortality in women who had never used estrogen therapy but not in past and current users: assuming a 35-year lifespan after oophorectomy: number needed to harm for all-cause death=8, coronary heart disease death=33, and lung cancer death=50.
CONCLUSIONS: Bilateral oophorectomy is associated with increased mortality in women aged younger than 50 years who never used estrogen therapy and at no age is oophorectomy associated with increased survival. LEVEL OF EVIDENCE: I.

Entities:  

Mesh:

Year:  2013        PMID: 23635669      PMCID: PMC4254662          DOI: 10.1097/AOG.0b013e3182864350

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  100 in total

1.  Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer.

Authors:  Koji Matsuo; James C Cripe; Katherine C Kurnit; Michiko Kaneda; Audrey S Garneau; Gretchen E Glaser; Aaron Nizam; Rachel M Schillinger; Michelle L Kuznicki; Akira Yabuno; Shiori Yanai; Denise M Garofalo; Jiro Suzuki; Jessica D St Laurent; Ting-Tai Yen; Annie Y Liu; Masako Shida; Mamoru Kakuda; Tetsuro Oishi; Shin Nishio; Jenna Z Marcus; Sosuke Adachi; Tetsuji Kurokawa; Malcolm S Ross; Max P Horowitz; Marian S Johnson; Min K Kim; Alexander Melamed; Karime K Machado; Kosuke Yoshihara; Yoshio Yoshida; Takayuki Enomoto; Kimio Ushijima; Shinya Satoh; Yutaka Ueda; Mikio Mikami; Bobbie J Rimel; Rebecca L Stone; Whitfield B Growdon; Aikou Okamoto; Saketh R Guntupalli; Kosei Hasegawa; Mian M K Shahzad; Dwight D Im; Marina Frimer; Bobbie S Gostout; Frederick R Ueland; Shoji Nagao; Pamela T Soliman; Premal H Thaker; Jason D Wright; Lynda D Roman
Journal:  Gynecol Oncol       Date:  2019-08-16       Impact factor: 5.482

Review 2.  Ovarian Cancer Prevention in High-risk Women.

Authors:  Sarah M Temkin; Jennifer Bergstrom; Goli Samimi; Lori Minasian
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

3.  Should Fallopian Tubes Be Removed During Hysterectomy Procedures? - A Statement by AGO Ovar.

Authors:  M Pölcher; S Hauptmann; C Fotopoulou; B Schmalfeldt; I Meinhold-Heerlein; A Mustea; I Runnebaum; J Sehouli
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

Review 4.  Long-term health consequences of premature or early menopause and considerations for management.

Authors:  S S Faubion; C L Kuhle; L T Shuster; W A Rocca
Journal:  Climacteric       Date:  2015-04-07       Impact factor: 3.005

Review 5.  Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants.

Authors:  Melissa Walker; Michelle Jacobson; Mara Sobel
Journal:  CMAJ       Date:  2019-08-12       Impact factor: 8.262

6.  Persistent Underutilization of BRCA1/2 Testing Suggest the Need for New Approaches to Genetic Testing Delivery.

Authors:  Anne Marie McCarthy
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

Review 7.  Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention.

Authors:  Anthony N Karnezis; Kathleen R Cho
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

Review 8.  Long term side effects of adjuvant chemotherapy in patients with early breast cancer.

Authors:  Jessica J Tao; Kala Visvanathan; Antonio C Wolff
Journal:  Breast       Date:  2015-08-20       Impact factor: 4.380

9.  Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.

Authors:  James Yarmolinsky; Caroline J Bull; Emma E Vincent; Jamie Robinson; Axel Walther; George Davey Smith; Sarah J Lewis; Caroline L Relton; Richard M Martin
Journal:  JAMA       Date:  2020-02-18       Impact factor: 56.272

Review 10.  Premature menopause and risk of neurological disease: basic mechanisms and clinical implications.

Authors:  Erin L Scott; Quan-Guang Zhang; Ratna K Vadlamudi; Darrell W Brann
Journal:  Mol Cell Endocrinol       Date:  2014-01-22       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.